Physicians' Academy for Cardiovascular Education

Agenda Topics ▼Video ▼Online-CME News ▼Meeting Reports Slides ▼About

AHA 2018 ▼Diabetes & CVD ▼Epigenetics in CVD ▼Expert Meeting GLP-1, CVD & T2DM ▼HFpEF: The essentials to know ▼Invest in your arteries ▼LDL-c & PCSK9i in Clinical Cardiology ▼PCSK9 ▼

HoFH

Feb. 8, 2015

Share this page with your colleagues and friends:

Continue reading:

5 Things a cardiologist should know about diabetes

Slide Curriculum: Diabetes and cardiology

Slides (curriculum) - July 24, 2018

PACE Special: 5 Things a cardiologist should know about diabetes

Download - Download your free copy

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

ACS

Long-term statin adherence inversely associated with all-cause mortality in ASCVD

Literature - Feb. 19, 2019 - Rodriguez F et al. - JAMA Cardiol 2019

PCSK9 inhibitor reduces first and subsequent nonfatal CV events and death after ACS

Literature - Feb. 11, 2019 - Szarek M et al., - J Am Coll Cardiol. 2019

Coronary plaque characteristics and CAC score in relation to CHD risk in CAD patients

Literature - Feb. 5, 2019 - Williams MC et al. - JACC 2019

Atherosclerosis

Diet with red meat as main protein source increases levels of TMAO, which is linked to atherogenesis

Literature - Feb. 19, 2019 - Wang Z et al., - Eur Heart J 2019

Increasing prevalence rates of modifiable risk factors in relatively young patients hospitalized for AMI

Literature - Feb. 19, 2019 - Yandrapalli S et al. - JACC 2019

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

Atrial fibrillation

AF patients with cognitive impairment or frailty less likely to receive OAC

Literature - Feb. 12, 2019 - Madhavan M et al. - Am Heart J 2019

Two genetic studies support causal relationship between thyroid function and AF

Literature - Jan. 29, 2019 - Salem et al, Ellervik et al. - JAMA Cardiol. 2018

Greater net clinical benefit of NOAC vs. warfarin in Asians with AF compared with non-Asians

Literature - Jan. 15, 2019 - Chao TF et al. - Eur Heart J 2018

CV Inflammation

Better oral hygiene behavior can positively modify the CV risks associated with poor oral health

Literature - Feb. 21, 2019 - Park S-Y et al,. - Eur Heart J. 2019

Modest Lp(a) lowering with PCSK9 inhibitor not enough to reduce arterial wall inflammation

Literature - Jan. 9, 2019 - Stiekema LCA et al. - Eur Heart J. 2018

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD

CVRM

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

What are the key issues and challenges impacting clinical management with novel therapeutics lowering cholesterol?

5' education - Feb. 6, 2019 - Kausik Ray, Gilles Montalescot

Diabetes & CVD: Time for a multifactorial approach

10' education - Dec. 6, 2018 - WCC Dubai, UAE - John E Deanfield, MD London, United Kingdom

Diabetes

Increasing prevalence rates of modifiable risk factors in relatively young patients hospitalized for AMI

Literature - Feb. 19, 2019 - Yandrapalli S et al. - JACC 2019

Regional symposium: Diabetes, Cardiology & Novel Therapeutic Approaches: Science, Outcomes and Practice

Agenda - Mar. 1, 2019 - Abu Dhabi, UAE

Large meta-analysis confirms efficacy of statins in primary CVD prevention, but individual benefit-harm profiles vary

Literature - Feb. 18, 2019 - Yebyo HG et al. - Am Heart J 2019

Expert Meeting GLP-1, CVD & T2DM

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya

Familial Hypercholesterolemia

Sustained LDL-c reduction upon dose adjustment of PCSK9 inhibitor

Literature - Feb. 20, 2019 - Dufour R et al., - J Clin Lipidol. 2019

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands

Better characterization of ASCVD risk in children with FH by measuring Lp(a) levels

Literature - Jan. 7, 2019 - Zawacki et al. - J Clin Lipidol 2018

GLP-1 RA & CVD

Treatment with GLP-1RA results in reduction of MACE in type 2 diabetes patients with established CVD

Literature - Feb. 12, 2019 - Hernandez AF et al. - The Lancet 2018

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

Translating outcomes to practice: Focus on GLP-1 RA, which patients will benefit?

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Neil Poulter MD - London, UK

Heart Failure

Striking underuse of therapies for HFrEF not explained by low blood pressure

Literature - Feb. 19, 2019 - Peri-Okonny PA et al., - JACC : Heart Failure 2019

Heart Failure, Diabetes & SGLT2i: Time to change practice?

Agenda - May 25, 2019 - Heart Failure 2019, Athens, Greece

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

HFpEF: The essentials to know

HFpEF: Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany

Slides: HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

Slides (presentation) - Aug. 27, 2018 - Carolyn Lam, MD - Singapore

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA

Hypertension

Bariatric surgery in obese subjects with hypertension results in improved BP outcomes

Literature - Feb. 19, 2019 - Schiavon CA et al. - Hypertension. 2019

Increasing prevalence rates of modifiable risk factors in relatively young patients hospitalized for AMI

Literature - Feb. 19, 2019 - Yandrapalli S et al. - JACC 2019

New recommendations of the ESC/ESH Guidelines on the management of hypertension

3' education - Feb. 11, 2019 - Prof. Bryan Williams - London, UK

Inflammation Expert Opinions

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Invest in your arteries

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

LDL-c & PCSK9i in Clinical Cardiology

Sustained LDL-c reduction upon dose adjustment of PCSK9 inhibitor

Literature - Feb. 20, 2019 - Dufour R et al., - J Clin Lipidol. 2019

Progressive CAD despite low LDL-C, an elusive disease?

5' education - Feb. 13, 2019 - Kausik Ray, Wouter Jukema

Large reduction of major vascular events with statins in older individuals

Literature - Feb. 11, 2019 - Cholesterol Treatment Trialists’ Collaboration - The Lancet 2019

Lipids

Sustained LDL-c reduction upon dose adjustment of PCSK9 inhibitor

Literature - Feb. 20, 2019 - Dufour R et al., - J Clin Lipidol. 2019

Long-term statin adherence inversely associated with all-cause mortality in ASCVD

Literature - Feb. 19, 2019 - Rodriguez F et al. - JAMA Cardiol 2019

Large meta-analysis confirms efficacy of statins in primary CVD prevention, but individual benefit-harm profiles vary

Literature - Feb. 18, 2019 - Yebyo HG et al. - Am Heart J 2019

Lp(a)

Treatment effect of PCSK9-inhibitor on major coronary events by baseline Lp(a) level in ASCVD

Literature - Jan. 21, 2019 - O’Donoghue ML et al. - Circulation 2018

Modest Lp(a) lowering with PCSK9 inhibitor not enough to reduce arterial wall inflammation

Literature - Jan. 9, 2019 - Stiekema LCA et al. - Eur Heart J. 2018

Better characterization of ASCVD risk in children with FH by measuring Lp(a) levels

Literature - Jan. 7, 2019 - Zawacki et al. - J Clin Lipidol 2018

PAH - Q&A

Pulmonary Arterial Hypertension: Key answers adressed

Online-CME - This course consists of 3 separate lectures

What is the underlying pathophysiology of PAH and what are its characteristics?

3' education - Jan. 11, 2017 - Bologna, Italy - Nazzareno Galiè, MD

Which clinical PH groups can be distinguished?

3' education - Jan. 10, 2017 - Bologna, Italy - Prof Nazzareno Galiè

PCSK9

Sustained LDL-c reduction upon dose adjustment of PCSK9 inhibitor

Literature - Feb. 20, 2019 - Dufour R et al., - J Clin Lipidol. 2019

Progressive CAD despite low LDL-C, an elusive disease?

5' education - Feb. 13, 2019 - Kausik Ray, Wouter Jukema

PCSK9 inhibitor reduces first and subsequent nonfatal CV events and death after ACS

Literature - Feb. 11, 2019 - Szarek M et al., - J Am Coll Cardiol. 2019

PCSK9 expert opinions

PCSK9 inhibition works, but you can’t force biology

10' education - Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Identification of patients who will benefit is important after FOURIER

10' education - Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

10' education - Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension: Key answers adressed

Online-CME - This course consists of 3 separate lectures

Why cardiologists should be more interested in PAH

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA

Novel insights in the management and prognosis of pulmonary hypertension

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy

Stroke

Large meta-analysis confirms efficacy of statins in primary CVD prevention, but individual benefit-harm profiles vary

Literature - Feb. 18, 2019 - Yebyo HG et al. - Am Heart J 2019

Treatment with GLP-1RA results in reduction of MACE in type 2 diabetes patients with established CVD

Literature - Feb. 12, 2019 - Hernandez AF et al. - The Lancet 2018

AF patients with cognitive impairment or frailty less likely to receive OAC

Literature - Feb. 12, 2019 - Madhavan M et al. - Am Heart J 2019

© 2006 - 2019 pace-cme.org - About